At a glance
ClinicalIndex Comparison RecordN/ACompleted· 49 enrolled
Drug / intervention
Topical combination therapyother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of the Tolerability of Using a Post Treatment Topical Adjuvant Combination Following Fractional Radiofrequency Ablation Using the Venus Viva
In Brief
A clinical study evaluating Topical combination therapy for Skin Disorders. Completed, enrolled 49 participants across 1 site.
Detailed Summary
The purpose of this study is to compare the tolerability of the application of a combination of a serum containing human bone marrow stem cell derived growth factor (SCR Complex) and cytokines and a botanical lipid-based occlusive (Bio Cel) immediately following fractional radiofrequency treatment using the Venus Viva versus standard of care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Disorders
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedSep 2016
Primary CompletionDec 2016
Study CompletionFeb 2017
TodayJul 2026
First PostedSep 12, 2016
Enrollment StartAug 1, 2016
Primary CompletionDec 1, 2016
Study CompletionFeb 27, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.8 years ago
Interventions
Topical combination therapyother